Beclomethasone Dipropionate

證據等級: L5

預測適應症: 1 個

Beclomethasone Dipropionate: From Asthma & Rhinitis to Atopic Eczema

One-Sentence Summary

Beclomethasone dipropionate (BDP) is a potent synthetic glucocorticoid widely established for inhaled asthma management and intranasal allergic rhinitis treatment, with its topical form already in standard use for inflammatory skin conditions. The TxGNN model predicts it may be effective for atopic eczema — specifically via oral or systemic administration in refractory cases — with 1 randomised controlled trial and 17 additional publications currently supporting this direction. With a TxGNN prediction score of 99.41%, the mechanistic rationale is strong, though evidence derives largely from older, small-scale studies and no modern registered clinical trials exist for this specific repurposing strategy.

Quick Overview

Item	Content
Original Indication	Asthma, allergic rhinitis, and inflammatory dermatoses (no New Zealand regulatory data available)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.41%
Evidence Level	L2
New Zealand Market Status	Not marketed
Number of Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Beclomethasone dipropionate acts on the glucocorticoid receptor (GR) to suppress the NF-κB and AP-1 signalling pathways, downregulating key Th2 inflammatory mediators including IL-4, IL-13, IL-31, and TSLP. It also reduces mast cell activation and eosinophil tissue infiltration — all of which are central drivers of atopic eczema pathophysiology. This mechanistic profile makes the TxGNN prediction highly plausible, and topical BDP is already an established treatment for inflammatory dermatoses within this disease spectrum.

The TxGNN prediction specifically points toward the repurposing potential of oral or systemic BDP for patients with severe, refractory atopic eczema who do not respond adequately to topical regimens alone. This concept is supported by direct clinical evidence: a 1984 double-blind, placebo-controlled crossover trial (PMID 6434024) demonstrated significant improvement in 26 children with severe atopic eczema treated with combined oral and nasal BDP over four weeks. A subsequent cohort study (PMID 1476023) achieved stable disease control in 10 of 14 paediatric patients with severe atopic dermatitis using oral BDP at approximately 1,000 µg/day.

The primary uncertainties relate to the systemic safety profile of oral BDP, particularly HPA axis suppression and linear growth retardation in children — as documented in multiple safety studies. Furthermore, the competitive landscape has shifted substantially: modern biologics such as dupilumab (anti-IL-4Rα) and tralokinumab (anti-IL-13) offer targeted Th2 blockade with superior long-term safety, which considerably raises the bar for any systemic corticosteroid strategy in this indication.

Clinical Trial Evidence

Currently no related clinical trials registered for beclomethasone dipropionate in atopic eczema.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6434024	1984	RCT	British Medical Journal	Double-blind, placebo-controlled crossover trial in 26 children with severe atopic eczema; combined oral + nasal BDP produced significant improvement vs placebo over 4 weeks; mild HPA suppression (reduced 24-hour urinary cortisol) observed
1476023	1992	Cohort	Acta Dermato-Venereologica Suppl.	Oral BDP (mean 1,000 µg/day, range 800–1,800) achieved stable disease control in 10/14 children with severe atopic dermatitis; growth deceleration documented at maintenance doses — key safety signal
14522624	2003	Cohort (Safety)	J Dermatol Treatment	Steroid wet-wrap therapy in 8 prepubertal children with atopic eczema; short-term growth (knemometry) and bone turnover (urinary DPD) monitored at 2-week intervals; identifies systematic assessment framework for paediatric steroid safety
30911861	2019	Formulation Study	AAPS PharmSciTech	Development of BDP-loaded pluronic mixed micelles in biocompatible hydrogel for enhanced dermal delivery in atopic dermatitis; sub-chronic animal model confirms local anti-inflammatory activity with reduced systemic exposure
8765824	1996	Experimental	J Allergy Clin Immunol	Topical steroids paradoxically enhance spontaneous in vitro IgE production in AD patients; highlights a potential limitation of glucocorticoid monotherapy and risk of relapse upon discontinuation
19874229	2009	Experimental	Immunopharmacol Immunotoxicol	Head-to-head comparison of mometasone furoate vs BDP in mouse models; mometasone showed greater local anti-inflammatory potency with lower systemic (adrenal) effects — relevant context for BDP's systemic risk profile
11488426	2001	Review	Japanese J Pharmacology	Overview of glucocorticoids in allergic diseases; BDP highlighted as an early inhaled agent; its efficacy in multiple allergic conditions supports broad anti-inflammatory applicability
19571596	2009	Review	Neuroimmunomodulation	Intranasal corticosteroids including BDP and their effects on the HPA axis; highlights cumulative adrenal suppression risk when multiple corticosteroid routes are combined — critical safety context for systemic BDP repurposing
9463794	1998	Review	Drugs	Topical mometasone (a 16α-methyl analogue of beclomethasone) review; BDP used as the potency reference comparator for atopic dermatitis treatment, confirming its established role in the dermatological glucocorticoid hierarchy
37023229	2023	Computational	J Chem Inf Model	DrugRep-KG knowledge graph framework for drug repurposing; demonstrates that graph-based unified latent space methods can recover known and novel drug-disease associations including BDP, providing independent computational corroboration

New Zealand Market Information

Beclomethasone dipropionate is currently not approved or marketed in New Zealand. No Medsafe authorisations were identified in the regulatory database (total licences: 0). Any clinical use in atopic eczema within New Zealand would require a Special Access Scheme (SAS) or Medicines Act Section 29 compassionate use pathway.

Safety Considerations

HPA Axis Suppression: Documented across multiple publications. Oral and systemic BDP suppresses the hypothalamic-pituitary-adrenal axis; 24-hour urinary cortisol excretion was measurably reduced even in the short 4-week RCT (PMID 6434024). Cumulative risk increases when combined with intranasal or inhaled corticosteroids (PMID 19571596).
Growth Retardation in Children: Linear growth deceleration was observed in children receiving oral BDP at 800–1,800 µg/day for atopic dermatitis (PMID 1476023), and short-term knemometric monitoring confirmed sensitivity of the growing skeleton to steroid exposure (PMID 14522624). Paediatric use requires structured growth surveillance.
IgE Rebound Risk: Topical glucocorticoids may paradoxically enhance spontaneous IgE production in some patients with atopic dermatitis (PMID 8765824), potentially contributing to relapse after discontinuation.
Systemic vs Topical Safety Gap: Comparative animal data suggest BDP carries greater systemic adrenal effects relative to newer glucocorticoids such as mometasone furoate at equivalent anti-inflammatory doses (PMID 19874229) — relevant when considering oral routes.

For full contraindications, drug interactions, and prescribing warnings, please refer to the product package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: While the mechanistic basis for BDP in atopic eczema is well-supported and early clinical evidence exists (1 small RCT, multiple cohort studies), there are no modern registered clinical trials, the drug carries documented systemic safety risks that are particularly concerning in paediatric populations, and highly effective targeted biologics now represent the standard of care for moderate-to-severe refractory atopic eczema — substantially narrowing the positioning opportunity for systemic BDP.

To proceed, the following is needed:

Regulatory gap closure: Obtain and review the full package insert/SPC for contraindications and warnings (Data Gap DG001 — currently Blocking)
MOA profile completion: Confirm full mechanism of action via DrugBank API query (Data Gap DG002 — currently High severity)
Modern clinical evidence: Prospective safety and efficacy data for oral BDP in atopic eczema using contemporary endpoints (EASI, IGA, DLQI) and monitoring standards
Comparative effectiveness analysis: Benchmark against dupilumab and tralokinumab to identify patient subgroups (e.g., biologic-ineligible, low-resource settings) where systemic BDP may still offer clinical value
Paediatric safety protocol: Structured growth monitoring and HPA function assessment plan if paediatric use is pursued
NZ regulatory pathway assessment: Feasibility analysis for Special Access Scheme or formal Medsafe application before any local clinical use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.